Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  systemic therapy
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Advanced skin melanoma – systemic treatment

100%
Kruczała M., Ziobro M., Grela-Wojewoda A., Cedrych I.
OncoReview
|
2015
|
vol. 5
|
issue 3
A133-138
EN
In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcomes. This review paper presents current knowledge on systemic treatment of advanced melanoma, including treatment availability in Poland.
2
Publication available in full text mode
Content available

Nasopharyngeal carcinoma – treatment possibilities in patients with primary metastatic carcinoma

100%
Kowalczyk M., Piątek M., Imielska-Zdunek D., Derra A., Zemła A., Boratyn-Nowicka A.
OncoReview
|
2017
|
vol. 7
|
issue 1
44-48
EN
This article presents methods of effective treatment of primary metastatic nasopharyngeal carcinoma, both causative and symptomatic, taking into account possible available treatment therapies (chemotherapy, targeted therapy, radiotherapy), and includes a case report. The applied treatment allowed for satisfactory control of the disease and much higher overall survival than expected – the patient survived for 53 months from the initial diagnosis and 41 months from being diagnosed with metastatic carcinoma.
3
Publication available in full text mode
Content available

Abiraterone acetate – 10 clinically relevant facts

100%
Żołnierek J.
OncoReview
|
2021
|
vol. 11
|
issue 3
80-84
EN
Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.